Western Australian Institute for Medical Research – 1999

1999 – $1.2 million research grant

Research Institution: Western Australian Institute for Medical Research, Royal Perth Hospital, Perth, Western Australia

Directors of Research: Professor’s Peter Klinken & Bruce Robinson

Cancer Type: Leukemia, breast cancer and prostate cancer, cervical cancer, pancreatic cancer, liver cancer and other cancers

Feature Outcome:

Establishment of eight state-of-the-art research facilities / Produced vaccine for cervical cancer

Further Details / Outcomes:

Establishment of eight state-of-the-art research facilities. Funds from the grant have been key in establishing the Institute’s network of research facilities. In addition the WA research tissue network and Lottries State Microarray facility have located into WAIMR premises, with their repository of cancer samples.

• Produced vaccine for cervical cancer.
• Professor Klinken’s group continues to study new genes they have discovered which play a role in the development of cancer and leukaemia.
• Professor Leedman’s team is examining new pathways within cells that may become deregulated in breast and prostate cancer.
• Associate Professor Minchin’s group is investigating genes that influence the way individuals deal with compounds in the environment that potentially cause cancer.
• Professor Robinson is at the leading edge of mesothelioma research.
• Associate Professor Ratajczak and Eidne are extending their group’s studies on hormone dependent cancers.
• Associate Professors Yeoh and Abraham have relocated into newly furbished laboratories, to enhance the efficiency of their work on liver cancer and lymphomas

Project Update:

• Establishment of eight state-of-the-art research facilities.
• Funds from the grant have been key in establishing the Institute’s network of research facilities. In addition the WA research tissue network and Lotteries State Microarray facility have located into WAIMR premises, with their repository of cancer samples.
• Collaboration on vaccine for cervical cancer.
• Professor Klinken’s group continues to study new genes they have discovered which play a role in the development of cancer and leukaemia.
• Professor Leedman’s team is examining new pathways within cells that may become deregulated in breast and prostate cancer.
• Associate Professor Minchin’s group is investigating genes that influence the way individuals deal with compounds in the environment that potentially cause cancer.
• Professor Robinson is at the leading edge of mesothelioma research.
• Associate Professor Ratajczak and Eidne are extending their group’s studies on hormone dependant cancers.
• Associate Professors Yeoh and Abraham have relocated into newly furbished laboratories, to enhance the efficiency of their work on liver cancer and lymphomas.